Hong Kong Medical Device Registration Cost and LRP Pricing 2026

How Much Does It Cost to Register a Medical Device in Hong Kong in 2026?

For a single foreign-manufactured device entering Hong Kong in 2026, expect a 3-year all-in budget of roughly USD 6,000–18,000 for an MD Class II / IVD Class B listing and USD 9,000–40,000 for an MD Class III–IV / IVD Class C–D listing, excluding Conformity Assessment Body (CAB) fees, certified translation for the upcoming statutory regime, and clinical evidence preparation. Government fees from the Department of Health Medical Device Division (MDD) are currently zero under the voluntary Medical Device Administrative Control System (MDACS), so the variance is not driven by the regulator. It is driven almost entirely by how your Hong Kong Local Responsible Person (LRP) bills you.

Three pricing models dominate the LRP market today, and the difference between the cheapest and most expensive can exceed 4x over three years for the same scope of work:

The MDD charges no government fee for MDACS listing — it is a free voluntary scheme under GN-01. Your LRP service fee is, in 2026, the entire registration cost. The Medical Device Bill currently in preparation (expected enactment 2026–2028) will introduce statutory fees, formalized LRP duties, and mandatory registration. The LRP contract you sign in 2026 is the contract that will carry your portfolio across the voluntary-to-statutory transition. This guide is about how to use that leverage.

Skip to Your Scenario

• Single MD Class II device, pre-revenue startup: Read Scenario A first — flat fee saves up to $7,000 in Year 1 cash.

• Single MD Class III–IV / IVD Class C–D device: Read Scenario B — Year 1 burden under hourly is 71% of 3-year cost.

• Multi-device portfolio (3+ devices): Read Scenario C — tier discounts compound dramatically.

• Already have an LRP and want to switch: Skip to the LRP Switching Playbook.

• Issuing an RFP this week: Skip to the RFP Template and 8 questions to ask.

• Want to validate the numbers: Read the Named Provider RFP Comparison.

• Worried about the upcoming Medical Device Bill: Read What 2026 Hong Kong Regulatory Churn Costs Under Each Pricing Model.

Why LRP Pricing Is Where Hong Kong Budgets Win or Lose

Hong Kong requires every foreign manufacturer without a local entity to appoint a Local Responsible Person — a Hong Kong-incorporated entity (or holder of a valid Hong Kong Business Registration Certificate) that holds the MDACS listing on the manufacturer's behalf, signs filings, manages importation authorization, files modifications and renewals, operates the complaint handling system, and serves as the MDD's point of contact for vigilance, recall coordination, and adverse event reporting under COP-01.

The LRP is not optional and not a one-time cost. The relationship runs as long as your device is on the Hong Kong market — under MDACS, listings are valid for 5 years and renewable indefinitely; under the upcoming statutory regime the LRP role is being formally codified as a permanent in-country obligation. Small differences in pricing model compound enormously over the device life.

This is one of the few line items in international registration where the buyer has real leverage: scope is standardized, multiple firms perform the same role, switching is possible, and government fees are public (currently zero). The catch: most LRP pricing is not published. You have to issue an RFP, sign an NDA, and compare proposals where every firm has a different scope inclusion list. Because government fees are zero, there is no other line item to absorb a bad pricing model.

The Three LRP Pricing Models, Decoded

Model 1: Hourly billing ("charge by hour")

The default for small-to-mid regulatory firms in Hong Kong. Scope sits in a Statement of Work; everything outside scope is billed at $115–$360/hour by tier. Hong Kong rates sit between Singapore (higher) and mainland China (lower):

(Source: MedDeviceGuide Medical Device Regulatory Consulting Hourly Rates by Region. Hong Kong rates were not previously benchmarked — these ranges are derived from regional comparators and observed Hong Kong RFP responses.)

Why buyers choose hourly: flexibility, perceived control, ability to use the LRP only when needed.

Why hourly is bad for buyers in practice:

• No incentive to be efficient. Every hour is revenue. There is no economic reason to optimize a process or reuse a template.

• Surprise invoices. "Quick check with MDD" becomes 4 hours. The bill arrives 30–60 days after.

• Scope creep is invisible until it bills. An IFU update for the bilingual (English/Traditional Chinese) requirement under TR-005 can be 2 hours or 20 — you find out after.

• Year 1 cash flow shock. First-year work (filing, conformity assessment coordination, translations, MDIS setup) is front-loaded and frequently 3–5x steady-state annual hours.

• Stage C compliance costs balloon. Devices needing MDACS listing for Department of Health / Hospital Authority procurement under Stage C (effective March 23, 2026) cannot wait — every billable hour of delay is a tendering window missed.

A typical MD Class III hourly engagement runs $14,000–$28,000 in Year 1 and $3,000–$7,000/year thereafter.

Model 2: Registration fee + lower annual maintenance

The dominant model for mid-to-large LRP service firms today. Buyer pays a one-time setup/registration fee plus a smaller recurring annual fee. Scope is bundled but each "extra" is an itemized add-on.

Typical structure:

The trap: the marketing message is "low annual fee," but Year 1 actual spend is usually $4,000–$14,000 because every listing triggers setup + filing + initial importation letters + (often) translation simultaneously.

Where this model fails buyers:

• Year 1 cash flow shock is structural. All major one-time fees fire in the same calendar year you have not yet started selling.

• Modifications are unbounded. Hong Kong's current regulatory environment (Stage C transition March 2026, Medical Device Bill drafting, GBA Connect catalog updates, IMDRF/CMDE reliance pathway expansion) generates 1–3 modification filings per device per year for active products. At $1,500/each, that is a $1,500–$4,500/year invisible tax.

• Importation letters scale with imports. Per-letter fees of $100–$300 mean monthly shippers pay $1,200–$3,600/year in administrative letters.

• The 5-year renewal cliff. At Year 5, MDACS renewal triggers a separate filing fee under most reg-plus-annual contracts.

• Statutory transition exposure. When the Medical Device Bill enacts, every existing MDACS listing will likely require a re-filing. Reg-plus-annual contracts treat that as billable scope. Flat-fee contracts typically do not.

Model 3: Flat all-inclusive annual fee

A newer model where the LRP charges a single annual fee covering initial filing, modifications, importation letters, English ↔ Traditional Chinese translations, MDIS correspondence, and 5-year renewal. Same number every year.

Two structural advantages: (1) the fee curve is flat, not front-loaded — Year 1 cost equals Year 2 cost; (2) the LRP's incentives align with yours — every additional hour is pure cost to them, so they are motivated to file cleanly and avoid MDD queries. The catch: flat-fee LRPs require multi-year contracts and exclude CAB fees, eventual statutory government fees, certified translations for non-MDD authorities, and importation handling itself.

The model is rare. As of April 2026, Pure Global is the only major LRP service provider that publishes a complete flat-fee schedule on its website (pureglobal.com/services/pricing) — the only published reference point for buyers comparing models.

Why this guide uses Pure Global as the worked example

We use Pure Global's published LRP rates because they are the only flat-fee rates in the public domain — verify at pureglobal.com/services/pricing. This is not an endorsement; the published rates simply enable apples-to-apples cash flow comparison that would otherwise require RFPs to multiple firms under NDA. Industry ranges for hourly and front-loaded models reflect typical RFP responses and procurement data collected by MedDeviceGuide.

Pure Global Hong Kong LRP Pricing (Published, April 2026)

MD Class I, Class II / IVD Class A, Class B

(Note: under MDACS, MD Class I and IVD Class A are outside the listing scope. Pure Global's tier exists for buyers who want LRP coverage anyway — common for manufacturers preparing for the Medical Device Bill transition or who want a single point of contact across their Hong Kong portfolio.)

MD Class III, Class IV / IVD Class C, Class D

Included in the annual fee — per Pure Global's published price list (verbatim from the xlsx Comments column: "preparation and submission of the registration, required translation, importation authorization, modifications, renewals, and correspondence with authorities"):

• Preparation and submission of the MDACS listing (initial registration filing via MDIS)

• Required translation of submission documents (English ↔ Traditional Chinese as required by the MDD)

• Importation authorization correspondence with the MDD

• Modifications to the listing (changes to device specs, labeling, intended use, manufacturer details)

• Renewals (the 5-year MDACS listing renewal filing)

• Correspondence with authorities (routine MDD communications on the listed devices, including queries and supplementary information requests)

Inherent to the Hong Kong LRP statutory role under MDACS COP-01 / GN-01 (included by definition, not separately billable):

• Complaint handling system operation — the LRP must operate a documented complaint handling system as a condition of holding an MDACS listing under COP-01

• Adverse event reporting coordination — the LRP is the manufacturer's point of contact for incident reporting to the MDD under COP-01 and the MDD's vigilance guidance

• Recall coordination point of contact — the LRP is the operational liaison for any field safety corrective action affecting Hong Kong-listed devices

Confirm scope before signing — these activities are not itemized on Pure Global's published price list, so verify in writing whether they sit inside the annual fee or are quoted separately:

• Coordination with reference country pathways (citing FDA 510(k)/PMA, EU CE, TGA, Health Canada, PMDA, NMPA, MFDS, or HSA approvals to support an MDACS submission) — typically a routine part of preparing a submission, but not separately enumerated in Pure Global's published Comments

• GBA Connect Scheme designation filings for cross-border use in mainland Chinese hospitals

• Annual surveillance reporting for high-risk tracked devices, where the MDD requests it

• Distributor authorization letters beyond the importation-authorization scope above (e.g., commercial distributor appointment paperwork that is not strictly an MDD filing)

• Migration to the statutory regime under the Medical Device Bill once enacted — see "Why the Statutory Transition Is the Real Story" below for why this clause matters most

Not included: Conformity Assessment Body (CAB) fees if the CAB pathway is used (BSI, SGS, TÜV SÜD); foreign-jurisdiction certification translation outside the MDD submission package; clinical evaluation drafting; future statutory government fees once the Medical Device Bill enacts (passed through at cost without markup); importation handling and customs brokerage by the LRP itself; ad-hoc consulting outside scope (billed at $200/hour per the published price list).

Contract Terms

• Standard contract: 3 years.

• Annual contract option: available, but the first-year fee is increased by 50%.

• Early termination: allowed at any time with a 50% payoff of the remaining contract value.

• Ad-hoc consulting (non-clients or out-of-scope work): $200/hour.

(Source: pureglobal.com/services/pricing, captured April 2026. Price list version 1.0, last updated 2026-01-12.)

3-Year Cash Flow: Side-by-Side Comparison

The pricing model only matters because of cash timing. The following scenarios show the same scope of work — one device, LRP only, government fees excluded (currently $0 anyway) — under each of the three models. Numbers are illustrative and based on the ranges given above.

Scope assumption. The Pure Global flat-fee column in these scenarios assumes that reference country pathway coordination (citing FDA / CE / TGA / Health Canada / PMDA / NMPA / MFDS / HSA approvals to streamline an MDACS submission) sits inside the published annual fee, since it is a routine part of "preparation and submission of the registration" — but it is not separately enumerated in Pure Global's published Comments column. Always confirm in writing whether this and other (C) "confirm with provider" items in the Scope Checklist are inside the annual fee. Pure Global's published price list itemizes preparation and submission, required translation, importation authorization, modifications, renewals, and correspondence with authorities; reference-country coordination, GBA Connect filings, and Medical Device Bill migration are not separately itemized.

Scenario A: Single MD Class II Device, 3-Year Total

The Year 1 burden under flat fee is $2,000 vs $9,000 under hourly for the same regulatory output. That $7,000 retained in Year 1 is, for an early-stage MedTech, often the difference between launching in Hong Kong this fiscal year and missing a Stage C tender window.

Scenario B: Single MD Class III–IV or IVD Class C–D Device, 3-Year Total

Under hourly, 72% of the 3-year LRP cost lands in Year 1 — the worst possible time for a Hong Kong entrant who has not yet won a Hospital Authority tender. Flat fee distributes the same work evenly, freeing roughly $20,500 of Year 1 working capital.

Scenario C: 5-Device Portfolio (3 MD Class II + 2 MD Class III–IV)

For multi-device portfolios, the flat-fee tier discount compounds. A 5-device portfolio at Pure Global's published rates costs less than a single MD Class III device under hourly billing. For manufacturers preparing for the Medical Device Bill's mandatory regime, the multi-device tier discount is the central argument for flat-fee LRP procurement now rather than after enactment.

What "All-Inclusive" Actually Means: Scope Checklist

When LRP proposals all claim to "include everything," the differences are in the fine print. Use this checklist to compare proposals line by line.

The scope items that quietly drive Year-2-and-beyond cost overruns under hourly and reg-plus-annual are: modifications, importation letters, MDD query responses, and bilingual translation refreshes. They generally account for 40–70% of post-Year-1 LRP spend.

A Hong Kong-specific line to watch: COP-01 LRP duties — complaint handling, adverse event reporting, recall coordination — are statutory LRP responsibilities, not optional services. Some hourly and reg-plus-annual contracts treat them as per-event billables. Under flat fee they are inside the annual fee because they are inside the LRP role.

What 2026 Hong Kong Regulatory Churn Costs Under Each Pricing Model

Hong Kong's medical device regulatory environment between 2022 and 2026 has been more active than at any point since MDACS was established in 2004. Each rule change forces existing listings to file modifications, regenerate IFU translations, or update labeling. Under hourly or reg-plus-annual, every filing is a billable event. Under flat fee, they are not — especially relevant given the Medical Device Bill on the near horizon.

Modification Volume from 2022–2026 Hong Kong MDD and Procurement Rules

The table below shows the cumulative modification load that a typical device on the Hong Kong market has had to absorb in the four years since the Stage A procurement reforms.

A typical MD Class II device with DOH exposure has filed 3–6 cumulative modifications/listing actions since 2022. MD Class III–IV devices, with broader scope and more complex bilingual labeling, are closer to 5–9 filings.

What That Modification Volume Costs You

Under hourly or reg-plus-annual, regulatory churn is a hidden tax that scales with how active the regulator is — not with how active you are. The MDD is currently among the more active Asia-Pacific medical device regulators because of the impending statutory transition. That is exactly the wrong environment to sign a 3-year hourly contract.

What Hong Kong Has Queued for 2026–2028: The Medical Device Bill Pipeline

The pipeline already in consultation or in preparation, each triggering fresh filings:

• Medical Device Bill (Hong Kong) — in preparation, expected enactment 2026–2028. Transforms MDACS from voluntary to mandatory statutory registration under the Centre for Medical Products Regulation (CMPR). Every existing voluntary listing will likely require migration. Anticipated: 1 mandatory re-filing per device, potentially with expanded technical file requirements.

• Formalized LRP role under the Bill. Current COP-01 duties become statutory obligations with enforcement powers. LRPs will likely need documented quality systems, staff qualifications, and possibly insurance.

• Government fees under the statutory regime. The zero-fee model is unlikely to persist. Singapore HSA, Australian TGA, and EU notified body fees are realistic comparators. Expect MDD/CMPR fees of HKD 5,000–50,000+ per device depending on class once the Bill enacts.

• GBA Connect Scheme expansion. 71 designated mainland Chinese hospitals as of December 2025; expansion to additional hospitals/device categories expected 2026–2027. Each catalog inclusion is a filing event.

• IMDRF / NMPA CMDE reliance pathway expansion. Existing listings may need re-filing to cite expanded reference approvals.

• Stage D procurement (anticipated) — extending mandatory listing beyond DOH. Not yet announced but consistent with the Stages A → B → C trajectory.

A reasonable 2026–2028 forecast for an existing MD Class III device is 3–5 additional filings (Medical Device Bill migration + Stage D + GBA expansion + NMPA reliance refresh + labeling clarification). At hourly rates, another $2,000–$10,000 per device. Under flat fee, $0.

For a 5-device MD Class III–IV portfolio, the difference between "modifications included" and "modifications billable" over 2026–2028 is roughly $10,000–$50,000 in net Hong Kong P&L impact.

Why the Statutory Transition Is the Real Story

The Medical Device Bill is the most important regulatory event in Hong Kong medical devices since MDACS was created in 2004. Every LRP contract signed in 2026 will straddle the transition.

• Hourly billing: the entire migration is a billable event. Expect a 2027–2028 spike of $5,000–$20,000 per device in transition work.

• Reg-plus-annual: migration triggers new "registration" fees because the Bill's mandatory regime is a fresh filing. Expect $3,000–$8,000 per device, often with a reset 5-year clock.

• Flat fee: migration is part of "all required filings with the authority" — same monthly economics whether the device sits under voluntary MDACS or statutory registration.

A contract you sign before the Bill enacts that explicitly includes "all required filings with the MDD or its successor authority" insulates you from the transition. One that does not hands the transition economics to your LRP.

When Flat Fee Wins, and When It Does Not

Flat fee is not universally the best choice. The decision framework:

Flat fee usually wins when:

• You expect to keep the device on the Hong Kong market for ≥3 years (which is most cases — Stage C alone makes a 5-year listing horizon the realistic baseline).

• You have ≥2 devices in your Hong Kong portfolio (tier discounts compound).

• Your devices target Department of Health or Hospital Authority procurement (Stage C creates ongoing labeling/listing activity).

• You are pre-revenue or capital-constrained in Year 1 and want to smooth cash outflow.

• You want certainty across the Medical Device Bill statutory transition (2026–2028).

• You participate in or are evaluating GBA Connect Scheme designations.

• You do not want to micromanage hourly billing or audit consultant invoices.

Hourly billing might still win when:

• You are doing a one-time discovery exercise (e.g., a Hong Kong market entry feasibility assessment) and do not yet have a listing to maintain.

• You have a single MD Class I or IVD Class A device that is outside MDACS scope and you do not anticipate needing LRP coverage at all (rare — most foreign manufacturers want a Hong Kong contact regardless).

• You need ad-hoc strategic counsel (e.g., responding to a Stage C tender disqualification) outside an existing LRP relationship.

Registration-fee-plus-annual is rarely the optimal choice on TCO grounds. It typically lands between hourly and flat fee on cost while preserving the cash flow problem of Year 1 front-loading — and it is also the model most exposed to re-filing fees when the Medical Device Bill enacts.

Government Fees: A Quick Reference

LRP service fees are excluded from MDD government fees in every model. For completeness, the official 2026 government fees are:

The flat-fee model's pass-through commitment matters more in Hong Kong than almost anywhere because today's $0 government fee is on a finite countdown. When the Medical Device Bill enacts, you want a contract that says "government fees passed through at cost without markup" — explicitly. Pure Global's published terms commit to that. Many competitor contracts reserve the right to add a "regulatory fee handling charge" once fees are introduced.

For a complete breakdown including CAB pricing, translation, and clinical evidence costs, see Hong Kong Medical Device Registration Guide: MDACS Listing, Local Responsible Person, and Transition Planning.

8 Questions to Ask Any LRP Before You Sign

This checklist works regardless of which LRP you are evaluating. Demand explicit, written answers before signing — not verbal assurances during the sales call.

1. Is the fee fixed for the contract term, or subject to annual escalation? If escalation: capped at what (CPI? HKD inflation index? uncapped?).

2. How many importation authorization letters are included per year? "Unlimited" should be in writing. "Reasonable use" is a red flag.

3. How many modifications are included per year? Is the cap per device or per portfolio? What counts as a modification (labeling? IFU? manufacturer change? class change? bilingual translation refresh?).

4. What is the per-hour rate for out-of-scope work? Some firms advertise low base fees and charge $400+/hour for anything outside scope.

5. Who pays if the MDD issues a request for supplementary information (RFI / query)? Under hourly, you do. Under flat fee, the LRP should. Confirm in writing.

6. What are the termination terms? Pure Global publishes 50% payoff of remaining contract value. Many competitors require full payoff or 12-month notice. This matters more than the headline price.

7. Will the LRP cover migration to the Medical Device Bill statutory regime at no additional charge, or will that be billed as a new registration? This is the highest-leverage clause in any 2026 Hong Kong LRP contract.

8. Does the LRP hold the listing or does the distributor? If a distributor holds your listing and you switch distributors later, you typically need to re-file the entire listing. Always insist on a listing held by an independent LRP, not by your importer.

If an LRP refuses to answer any of these in writing, that is the answer to the question.

LRP Switching Playbook: How to Leave Without Getting Trapped

The single most expensive mistake in LRP selection is signing a contract you cannot exit affordably. Many foreign manufacturers discover, 18 months in, that their LRP is mediocre but switching costs more than staying. This section is the operational playbook competitors avoid publishing.

The MDACS Holder Change Procedure

The MDD permits transfer of LRP for both general medical device and IVD listings. The mechanic:

The bottleneck is almost always step 2. The MDD cannot process a holder change without consent from the outgoing LRP, who can stall on this single document.

Contract Termination Clauses: How They Actually Compare

The termination clause buried in your LRP agreement is often more economically consequential than the headline annual fee. Common terms in the market:

A typical industry LRP contract requiring 12 months notice plus 100% payoff plus a transfer fee makes mid-contract switching on a $5,000/year deal cost $5,000 + $10,000 + $2,500 = $17,500 before paying the new LRP a cent — more than 5 years of flat-fee under Pure Global's published rate for a single MD Class II listing.

The Distributor-as-LRP Lock-In Trap

The most common trap for first-time Hong Kong entrants: letting the in-country distributor double as the LRP. The distributor often offers LRP services "for free" as part of the commercial deal. The economic reality is harsher.

If your distributor holds the MDACS listing:

• Switching distributors often requires re-listing, not just a holder transfer. The MDD may treat a fresh BR certificate as a fresh filing — $3,000–$10,000 in LRP fees and 3–12 months during which you cannot supply the public sector under Stage C.

• The distributor gains implicit veto over Hong Kong commercial strategy. They can refuse parallel importation letters, drag transfer letters, or threaten re-listing delay during margin renegotiation.

• The "free LRP" is priced into distributor margin. Hong Kong practice is 8–18% commercial markup. For a HKD 30M/year (USD 3.8M) Hong Kong business, that is USD 300,000–700,000/year in implicit LRP cost.

The right structure: an independent LRP holds the MDACS listing, with one or more distributors as authorized importers under it. Switching distributors becomes a commercial decision, not a regulatory one. This trap is especially costly under Stage C, where any listing interruption disqualifies you from public-sector tenders.

Clean Switching: 7-Step Sequencing

1. Sign the new LRP first, with the contract conditional on successful transfer of named listings.

2. Generate fresh manufacturer appointment letters in English and Traditional Chinese.

3. Time the notice letter to land 30 days before the contract anniversary to minimize early-termination cost.

4. Cite specific contract clauses in your termination letter — especially the transfer letter delivery commitment.

5. File the holder change via MDIS the day you receive consent — do not wait for batch processing.

6. Hold importation letter coverage continuous — the incoming LRP issues authorizations from MDD approval date. Gaps mean stuck shipments and Stage C tender exposure.

7. Confirm MDIS account credentials transfer cleanly — the listing record is tied to the LRP.

A clean switch costs $1,500–$4,000 and 60–120 days. A poor one can cost a year of market access. The termination clause is the upstream variable — negotiate it hardest before signing.

Named Provider RFP Comparison: Pure Global vs Typical Competitor Quotes

We modeled the same scope — a single MD Class II device entering Hong Kong, 3-year LRP relationship, all standard inclusions — under three pricing structures: Pure Global (rates verified on its public pricing page), and two composite industry quotes built from typical Hong Kong LRP RFP responses. Composite columns use range midpoints. Competitors are not named individually because they do not publish prices and we cannot publish their proposals without consent.

Same Scope, Three Models, 3-Year Total

Scope baseline: 1 MD Class II medical device, MDACS listing under GN-02, foreign manufacturer using FDA 510(k) reference country pathway, 3-year contract, average import volume (6 importation letters/year), 1–2 modifications per year (consistent with 2026 Hong Kong Stage C and Medical Device Bill churn).

(Pure Global rates verified at pureglobal.com/services/pricing. Composite ranges drawn from typical Hong Kong LRP RFP responses observed by MedDeviceGuide; individual firm numbers vary.)

Key Takeaways from the Comparison

• Pure Global at the published rate is 3.2x cheaper than the composite hourly quote over 3 years, and 2.4x to 4.9x cheaper than the composite reg+annual quote.

• The cost gap widens in Years 2–3 if modifications run above average — likely under 2026 Hong Kong churn (Stage C, Medical Device Bill drafting, GBA Connect updates, NMPA reliance expansion).

• Reg-plus-annual has the widest bracket because providers vary on whether modifications and importation letters are inside the annual fee. Read every "included" claim line by line.

• Flat fee is insulated from invoice variance. Hourly and reg-plus-annual are most exposed to the Medical Device Bill transition; flat-fee contracts that include "all required filings with the MDD or its successor authority" are not.

Why Composite Instead of Named Competitors

No other major LRP provider publishes its prices, so naming Firm X with a specific number invites disputes we cannot resolve without violating NDAs on observed proposals. Every firm's quote also varies by negotiation, scope inclusion, and volume — single-firm naming gives a misleadingly precise picture. The point is the structural difference between pricing models. The next section gives you a template designed to force apples-to-apples comparisons in your own RFP.

LRP RFP Template Copy and Paste

Most LRP RFPs come back in three different formats with three different scope lists, making side-by-side comparison nearly impossible. Use the template below to force every responding firm into the same structure.

Subject: Request for Proposal — Hong Kong Local Responsible Person (LRP) Services for [Manufacturer Name]

Dear [Provider],

[Manufacturer Name] is evaluating Hong Kong Local Responsible Person service providers for our medical device portfolio entering or maintaining presence in the Hong Kong market under MDACS, with anticipated transition to the statutory regime under the upcoming Medical Device Bill. We are issuing this RFP to [N] firms and request a written proposal by [date].

Portfolio Scope

#	Device Name	MDACS Class (MD I–IV / IVD A–D)	Reference Country Approval(s)	Currently Listed in HK?	Anticipated Modifications/Year
1	[Device A]	[Class]	[FDA / CE / TGA / Health Canada / PMDA / NMPA / MFDS / HSA]	[Yes / No]	[N]
2	[Device B]

Contract Term: We anticipate a [3-year / 5-year] LRP relationship, spanning the anticipated Medical Device Bill enactment.

Required Pricing Format

Please provide pricing in the following table for each year of the contract term. Indicate explicitly whether each line item is included in the base fee or billed separately, and if separately, on what unit basis.

Service Item	Year 1 Cost	Year 2 Cost	Year 3 Cost	Inclusion (Y/N)	Per-Unit Rate if Separate
Initial MDACS listing filing per device
English ↔ Traditional Chinese translation of submission documents
Importation authorization correspondence — please state limit
Modifications — please state limit
MDD query / supplementary information response
Reference country pathway coordination
5-year listing renewal
Distributor authorization letters
COP-01 LRP duties (complaint handling, AE reporting, recall coordination)
Annual surveillance reporting (high-risk tracked devices)
GBA Connect Scheme designation filings
Migration to statutory regime under Medical Device Bill
Out-of-scope hourly rate (T1 / T2 / T3)

Required Disclosures

1. Annual fee escalation clause — fixed, CPI-linked, HKD-inflation-linked, or uncapped?

2. Notice period required for non-renewal at end of term.

3. Early termination payoff — what percentage of remaining contract value?

4. Transfer letter delivery commitment in days from termination notice.

5. Any separate "transfer fee" charged at exit — yes/no, amount.

6. Future government fees under the Medical Device Bill — confirm passed through at cost without markup.

7. Whether you hold the listing in trust or as an agent — and whether you assert any right to withhold the MDACS listing certificate during a dispute.

8. Whether you commit to re-filing under the statutory regime at no additional fee, or whether such re-filing will be a billable event.

Evaluation Criteria

We will evaluate proposals on (in order): (1) total 3-year cost at our forecast scope, (2) inclusion completeness — fewer separately-billed line items is better, (3) Medical Device Bill transition coverage, (4) termination clause flexibility, (5) responsiveness during this RFP, (6) MDACS filing track record (please attach 2–3 references).

Please respond by [date] to [contact email].

Best regards,

[Your Name]

[Your Title], [Manufacturer Name]

This forces every LRP to price the same scope. The items firms diverge on — modifications, importation letters, query responses, statutory transition coverage, termination — are the items the template forces them to disclose. After three to five proposals come back in this format, the right answer is usually obvious within an hour.

Frequently Asked Questions

Is a Hong Kong LRP the same as a distributor?

No. An LRP holds the MDACS listing and acts as the MDD's regulatory point of contact under COP-01 (complaint handling, AE reporting, recall coordination). A distributor imports and sells commercially. Combining the roles means the distributor controls the listing — when the relationship sours you cannot leave without re-listing, with Stage C tender exposure.

Can I be my own LRP?

Only with a Hong Kong-incorporated entity (or holder of a valid Hong Kong BR Certificate) and the operational capacity for COP-01 duties. For the first 5–10 devices, an independent LRP is typically cheaper than incorporating.

How long does an LRP transition take?

60–150 days for MD Class II / IVD B; 90–210 days for MD Class III–IV / IVD C–D. The outgoing LRP must consent; the MDD processes the holder change via MDIS. Pure Global's 50% remaining-contract-value early-termination clause is among the more buyer-friendly — many competitors require 100% payoff plus 6–12 months notice.

Are there really no government fees in Hong Kong?

Correct, as of April 2026. MDACS listing under the voluntary scheme is free — initial filing, modifications, and 5-year renewal. The Medical Device Bill (expected enactment 2026–2028) is widely expected to introduce statutory fees, but the schedule has not been published.

What happens to my MDACS listing when the Medical Device Bill enacts?

Grandfathering provisions are signaled but not finalized. Realistic expectation: all existing voluntary listings migrate to statutory registration, likely with expanded technical files, a fresh 5-year clock, and new government fees. A flat-fee contract covering "all required filings with the MDD or its successor authority" insulates you from the LRP economics of that migration.

Can I negotiate the flat-fee price?

Pure Global publishes the price, so the published rate is the rate. Negotiable variables are scope (number of listings, contract length). For 11+ portfolios, custom pricing applies.

What is GBA Connect, and does my LRP handle it?

The Greater Bay Area Connect Scheme allows Hong Kong-listed devices into 71+ designated mainland Chinese hospitals without full NMPA registration — an important stepping-stone angle for foreign manufacturers entering mainland China. Most LRPs handle catalog submissions as billable extras; flat-fee contracts that include "all designation filings" cover it inside the annual fee.

How does Hong Kong LRP cost compare to other markets?

Hong Kong's LRP cost ($2,000–$8,000/year flat fee) sits between Singapore's HSA Registrant ($2,500–$6,000/year) and mainland China's NMPA Agent ($5,000–$15,000/year). Hong Kong is exceptionally cheap on government-fee terms (zero today vs. RMB 40,000–100,000+ for NMPA). See Medical Device Registration Cost by Country: 2026 Global Comparison.

Should I list now or wait for the Medical Device Bill?

List now. (1) Stage C effective March 23, 2026 already excludes unlisted devices from DOH/HA procurement; (2) existing MDACS listings likely receive favorable grandfathering; (3) building the LRP relationship under the simpler voluntary regime is cheaper than starting fresh under mandatory regulation.

Bottom Line

Hong Kong's government fees are zero — for now. Your LRP service fee is the entire registration cost, so the pricing model you sign in 2026 is 100% of what you spend on Hong Kong access. Hourly billing front-loads 60–72% of 3-year cost into Year 1; reg-plus-annual front-loads 48–56%; flat fee distributes evenly. Layer in the Medical Device Bill on the 2026–2028 horizon and the calculus tightens — a flat-fee contract covering "all required filings with the MDD or its successor authority" carries you across the statutory transition at no marginal cost. Every other model treats the transition as billable. The numbers are 2026 benchmarks; the pricing model questions are timeless. Ask them before you sign.

Related Guides

• Hong Kong Medical Device Registration Guide: MDACS Listing, Local Responsible Person, and Transition Planning

• Brazil Medical Device Registration Cost 2026: BRH Pricing Models, Flat Fee vs Hourly Billing, and 3-Year Cash Flow Comparison

• Medical Device Registration Cost by Country: 2026 Global Comparison

• Medical Device Regulatory Consulting Hourly Rates by Region

• Singapore HSA Medical Device Registration Guide

• China NMPA Medical Device Registration Guide